NextCure, Inc. Cash Flow Statement
NXTC|3 years of annual SEC 10-K data (FY2019-FY2021)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$45M
FY2021
Free Cash Flow
-$52M
FY2021
Capital Expenditures
$7M
Cash used for long-term assets
Dividends Paid
N/A
FY2021
NextCure, Inc. used $45M in operating cash flow and negative free cash flow of $52M in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Net Income | -$36.6M | -$33.7M | -$22.8M |
| Depreciation & Amortization | $3.4M | $2.7M | $1.7M |
| Operating Cash Flow | -$45.0M | -$35.6M | $8.0M |
| Capital Expenditures | $7.1M | $3.4M | $3.1M |
| Free Cash Flow | -$52.1M | -$39.0M | $4.9M |
| FCF Margin | -232.8% | -614.4% | 77.7% |